Novel immunomodulators based on an oxazolin-2-one-4-carboxamide scaffold

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Organic Synthesis

Background:

• Sphingosine-1-phosphate (S1P) receptor modulators are crucial in treating autoimmune diseases.
• Existing therapies like FTY720 have limitations, necessitating the development of novel agonists.
• Non-phosphate S1P receptor agonists offer a potentially safer therapeutic profile.

Purpose of the Study:

• To design and synthesize novel non-phosphate oxazolidin-2-one-4-carboxylic amide derivatives as S1P(1) receptor agonists.
• To evaluate the in vitro and in vivo efficacy and safety of these novel compounds.
• To identify a lead compound for further optimization as an immunomodulator.

Main Methods:

• Synthesis of oxazolidin-2-one-4-carboxylic amide compounds (1a-f).
• Single crystal X-ray diffraction to determine the structure of compound 1e.
• S1P(1) Redistribution® assay to assess receptor agonist activity (EC50 determination).
• Cytotoxicity assays and in vivo immunosuppressive effect evaluation.

Main Results:

• Compounds 1a-f were successfully synthesized and characterized.
• Compounds 1a-d exhibited S1P(1) receptor agonist activity with EC50 values in the micromolar range.
• Cytotoxicity of compounds 1a-d was significantly lower (8-40 fold) than FTY720.
• Compound 1a demonstrated comparable in vivo immunosuppressive effects to FTY720 at a 10 mg/Kg dose, despite weaker in vitro potency.

Conclusions:

• Oxazolidin-2-one-4-carboxylic amide derivatives represent a novel class of non-phosphate S1P(1) receptor agonists.
• Compound 1a shows significant potential as an immunomodulatory agent and serves as a promising lead compound.
• Further medicinal chemistry modifications and molecular modeling are warranted to enhance affinity and clinical therapeutic properties.